Secondary failure: immune responses to approved protein therapeutics
Author:
Funder
US Food and Drug Administration
Publisher
Elsevier BV
Subject
Molecular Biology,Molecular Medicine
Reference73 articles.
1. Recent advances in (therapeutic protein) drug development;Lagassé;F1000Res,2017
2. Biopharmaceutical benchmarks 2018;Walsh;Nat. Biotechnol.,2018
3. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa;Lentz;J. Thromb. Haemost.,2014
4. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity;Mahlangu;J. Thromb. Haemost.,2015
5. T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation – updated consensus and review 2020;Jawa;Front. Immunol.,2020
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Engineering Approaches for Exosome Cargo Loading and Targeted Delivery: Biological versus Chemical Perspectives;ACS Biomaterials Science & Engineering;2024-06-28
2. Emerging approaches to induce immune tolerance to therapeutic proteins;Trends in Pharmacological Sciences;2023-12
3. The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity;Frontiers in Immunology;2023-10-16
4. A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII;Heliyon;2023-06
5. Current Strategies for Exosome Cargo Loading and Targeting Delivery;Cells;2023-05-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3